Idorsia Ltd (IDRSF)
OTHER OTC:IDRSF
IDRSF Stock Chart & Stats
$4.32
$0.06(7.06%)
At close: 4:00 PM EST
$4.32
$0.06(7.06%)
Day’s Range― - ―
52-Week Range$2.25 - $7.70
Previous CloseN/A
Volume601.00
Average Volume (3M)314.00
Market Cap
$1.81B
Enterprise Value$2.22B
Total Cash (Recent Filing)$94.70M
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Jul 30, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding255,040,510
10 Day Avg. Volume202
30 Day Avg. Volume314
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue10.15
Enterprise Value/Gross Profit11.55
Enterprise Value/Ebitda-15.48
Forecast
1Y Price Target
$5.77Price Target Upside33.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$279.94M
Bulls Say, Bears Say
Bulls Say
High Product-level Gross MarginsVery high gross margins (~90%) indicate strong product economics and pricing power at the unit level. Over the medium term this provides structural flexibility: product profits can absorb high R&D and SG&A, support reinvestment or partner deals, and improve operating leverage if fixed costs are controlled.
Demonstrated Revenue Scale-up (multi-year)Revenue grew materially from 35.3M in 2021 to 221.0M in 2025, showing the company can commercialize products and scale sales over time. This track record indicates an operational ability to build distribution, secure reimbursement, and generate recurring product revenues beyond one-off events.
Improving Cash Burn Trend Vs Earlier YearsManagement has reduced cash outflows relative to prior periods, showing progress in slowing burn. This trend, if sustained, lengthens runway and increases optionality for reaching regulatory or commercial inflection points without immediate reliance on dilutive financing.
Bears Say
Highly Stressed Balance Sheet And LeverageDebt far exceeds assets and equity is deeply negative, creating refinancing and covenant risk. Structurally, heavy leverage limits strategic flexibility, raises funding costs, and increases the probability that near-term financing needs will dictate asset sales, partnerships, or dilutive capital raises.
Persistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow implies the business consumes cash to fund operations and growth. Over months this pressure requires external financing or deal monetization, constraining discretionary R&D or commercial investment and increasing execution risk.
Negative Profitability And Volatile RevenuesA sharp TTM revenue decline combined with deep operating losses signals structural demand or product lifecycle issues and undermines path to profitability. Persistent negative margins reduce internal funding capacity and raise dependence on external partners or milestone payments for sustainability.
IDRSF FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was $2.25 and its highest was $7.70 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is $1.81B.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Jul 30, 2026 which is in 35 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Apr 28, 2026. The company reported -$0.174 earnings per share for the quarter, beating the consensus estimate of -$0.23 by $0.056.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd does not currently pay dividends.
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.24.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 255,040,510 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -$0.174 in its last earnings report, beating expectations of -$0.23. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in IDRSF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
IDRSF Stock 12 Month Forecast
Average Price Target
$5.77
▲(33.63% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Ownership Overview
―
Insiders
3.95% Mutual Funds
― Other Institutional Investors
94.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---